Targeted Protein Degraders: Transforming Oral Therapeutics

By Rebecca Coutts, Ph.D., Senior Director, Pharmaceutical Development

Targeted protein degraders (TPDs) are transforming modern drug discovery. Unlike traditional drugs that just block proteins, TPDs harness the body's natural processes to completely eliminate disease-causing proteins. This approach is opening up new treatment possibilities for conditions that were once considered untreatable, especially in oncology, neurodegenerative disorders, and immune-related diseases.

The potential of TPDs has attracted significant investment, with venture financing soaring from $33 million in 2017 to $707 million in 2022—an increase of over 2,000%. The global market, valued at around $544.4 million in 2024, is projected to grow at a compound annual growth rate (CAGR) of 20.8% from 2025 to 2030. However, despite their promise, TPDs still face major challenges related to formulation, bioavailability, and manufacturing scalability.